Treatment of hibernating myocardium and diabetic...

Details Treatment of hibernating myocardium and diabetic... Treatment of hibernating myocardium and diabetic...

2005-05-17

2005-05-17

Meller, Michael (Department: 1654)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

Reexamination Certificate

active

06894024

ABSTRACT:
Hibernating myocardium is characterized by viable myocardium with impaired function due to localized reduced perfusion. Hibernating myocytes retain cellular integrity, but cannot sustain high-energy requirements of contraction. High plasma levels of catecholamines, such as norepinepherine, are believed to be predictive of mortality from hibernating myocardium. Likewise, high levels of catecholamines lead to cardiomyopathy in patients with diabetes. GLP-1 reduces plasma norepinepherine levels, and it thus is useful in a method of treating hibernating myocardium or diabetic cardiomyopathy.

REFERENCES:
patent: 6235481 (2001-05-01), Horikawa et al.
patent: 6277819 (2001-08-01), Efendic
patent: 6399601 (2002-06-01), Du Bois
patent: 6441015 (2002-08-01), Aspnes et al.
patent: 9940788 (1999-08-01), None
patent: 0034332 (2000-06-01), None
International Search Report of International Application No. PCT/US01/32559, dated Mar. 18, 2003.
Cai and Kang, “Oxidative Stress and Diabetic Cardiomyopathy”,Cardiovascular Toxicology, vol. 1, No. 3, pp. 181-193 (2001).

Affiliated with

Also associated with

Rating

Treatment of hibernating myocardium and diabetic... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Treatment of hibernating myocardium and diabetic..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of hibernating myocardium and diabetic... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3438608